Anil Vachani

Anil Vachani

Auto-generated profile, based on publicly available information

Anil Vachani

University of Pennsylvania, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Chest
Verified
Journal Article
Open access
AVAnil Vachani
Anil Vachani
FMFabien Maldonado
Fabien Maldonado
BLBalaji Laxmanan
Balaji Laxmanan
IKIftekhar Kalsekar
Iftekhar Kalsekar
SMSeptimiu Murgu
Septimiu Murgu

6 June 2024 in Cancer Discovery
Verified
Journal Article
Open access
PMPeter Mazzone
Peter Mazzone
PBPeter B Bach
Peter B Bach
JCJacob Carey
Jacob Carey
CSCaitlin A. Schonewolf
Caitlin A. Schonewolf
KBKatalin Bognar
Katalin Bognar
LPLuke R.G. Pike
Luke R.G. Pike
Lung cancer screening via annual low-dose computed tomography has poor adoption. We conducted a prospective case–control study among 958 individuals eligible for lung cancer screening to develop a blood-based lung cancer detection test that when positive is followed by a low-dose computed tomography. Changes in genome-wide cell-free DNA fragmentation profiles (fragmentomes) in peripheral blood reflected genomic and chromatin characteristics of lung cancer. We applied machine learning to fragmentome features to identify individuals who were more or less likely to have lung cancer. We trained the classifier using 576 cases and controls from study samples and validated it in a held-out group of 382 cases and controls. The validation demonstrated high sensitivity for lung cancer and consistency across demographic groups and comorbid conditions. Applying test performance to the screening eligible population in a 5-year model with modest utilization assumptions suggested the potential to prevent thousands of lung cancer deaths. Significance: Lung cancer screening has poor adoption. Our study describes the development and validation of a novel blood-based lung cancer screening test utilizing a highly affordable, low-coverage genome-wide sequencing platform to analyze cell-free DNA fragmentation patterns. The test could improve lung cancer screening rates leading to substantial public health benefits. See related commentary by Haber and Skates, p. 2025

1 September 2022 in Radiology
Verified
Journal Article
Closed access
RKRoger Y. Kim
Roger Y. Kim
JOJason L. Oke
Jason L. Oke
LPLyndsey C. Pickup
Lyndsey C. Pickup
RMReginald F. Munden
Reginald F. Munden
TDTravis L. Dotson
Travis L. Dotson
AVAnil Vachani
Anil Vachani
An artificial intelligence–based computer-aided diagnosis tool improved radiologists’ and pulmonologists’ risk stratification of indeterminate pulmonary nodules on chest CT scans. Background Limited data are available regarding whether computer-aided diagnosis (CAD) improves assessment of malignancy risk in indeterminate pulmonary nodules (IPNs). Purpose To evaluate the effe...

7 September 2022 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
AVAnil Vachani
Anil Vachani
NCNikki M. Carroll
Nikki M. Carroll
MSMichael J. Simoff
Michael J. Simoff
CNChristine Neslund-Dudas
Christine Neslund-Dudas
SHStacey Honda
Stacey Honda
DRDebra P. Ritzwoller
Debra P. Ritzwoller

20 June 2022 in Journal of the American College of Radiology
Verified
Journal Article
Open access
AVAnil Vachani
Anil Vachani
MZMeijia Zhou
Meijia Zhou
SGSudip Ghosh
Sudip Ghosh
SZShumin Zhang
Shumin Zhang
PSPhilippe Szapary
Philippe Szapary
IKIftekhar Kalsekar
Iftekhar Kalsekar
To provide recent population-based estimates of transthoracic needle biopsy (TTNB) complications and risk factors associated with these complications. This retrospective cohort analysis included adults from a nationally representative longitudinal insurance claims data set who underwent TTNB in 2017 or 2018. Complications that were evaluated included pneumothorax, hemorrhage, and air embolism. Separate logistic regression models estimated the association of pneumothorax or hemorrhage with the setting of care (ie, inpatient or outpatient) and selected baseline patient demographic and clinical characteristics including age, gender, history of chronic obstructive pulmonary disease, diagnosis of pleural effusion, tobacco use, use of oral anticoagulants and antiplatelet agents, prior lung cancer screening, previous bronchoscopy within 1 year, and Elixhauser comorbidity index. Among 16,971 patients who underwent TTNB, 25.8% experienced a complication within 3 days of the procedure (pneumothorax 23.3%, hemorrhage 3.6%, and air embolism 0.02%). Among patients who experienced pneumothorax, 31.9% required chest tube drainage. Among patients undergoing an outpatient TTNB (n = 12,443), 6.9% were hospitalized within 7 days. Biopsy in an inpatient setting, chronic obstructive pulmonary disease diagnosis, and prior bronchoscopy were associated with higher rates of both pneumothorax and hemorrhage. Prior lung cancer screening was associated with an increased risk of pneumothorax, and prior use of oral anticoagulants or antiplatelets was associated with higher rates of hemorrhage. This contemporary population-based cohort study demonstrated that approximately one-quarter of patients undergoing TTNB experienced a complication. Pneumothorax was the most frequent complication, and hemorrhage and air embolism were rare. Among outpatients, complications from TTNB are an important cause of hospitalization.

1 September 2022 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
RKRoger Y. Kim
Roger Y. Kim
KRKatharine A. Rendle
Katharine A. Rendle
NMNandita Mitra
Nandita Mitra
CSChelsea A. Saia
Chelsea A. Saia
CNChristine Neslund-Dudas
Christine Neslund-Dudas
AVAnil Vachani
Anil Vachani
Rationale: Black patients receive recommended lung cancer screening (LCS) follow-up care less frequently than White patients, but it is unknown if this racial disparity persists across both decentralized and centralized LCS programs. Objectives: To determine adherence to American College of Radiology Lung Imaging Reporting and Data System (Lung-RADS) recommendations among individuals undergoing LCS at either decentralized or centralized programs and to evaluate the association of race with LCS adherence. Methods: We performed a multicenter retrospective cohort study of patients receiving LCS at five heterogeneous U.S. healthcare systems. We calculated adherence to annual LCS among patients with a negative baseline screen (Lung-RADS 1 or 2) and recommended follow-up care among those with a positive baseline screen (Lung-RADS 3, 4A, 4B, or 4X) stratified by type of LCS program and evaluated the association between race and adherence using multivariable modified Poisson regression. Results: Of the 6,134 total individuals receiving LCS, 5,142 (83.8%) had negative baseline screens, and 992 (16.2%) had positive baseline screens. Adherence to both annual LCS (34.8% vs. 76.1%; P < 0.001) and recommended follow-up care (63.9% vs. 74.6%; P < 0.001) was lower at decentralized compared with centralized programs. Among individuals with negative baseline screens, a racial disparity in adherence was observed only at decentralized screening programs (interaction term, P < 0.001). At decentralized programs, Black race was associated with 27% reduced adherence to annual LCS (adjusted relative risk [aRR], 0.73; 95% confidence interval [CI], 0.63–0.84), whereas at centralized programs, no effect by race was observed (aRR, 0.98; 95% CI, 0.91–1.05). In contrast, among those with positive baseline screens, there was no significant difference by race for adherence to recommended follow-up care by type of LCS program (decentralized aRR, 0.95; 95% CI, 0.81–1.11; centralized aRR, 0.81; 95% CI, 0.71–0.93; interaction term, P = 0.176). Conclusions: In this large multicenter study of individuals screened for lung cancer, adherence to both annual LCS and recommended follow-up care was greater at centralized screening programs. Black patients were less likely to receive annual LCS than White patients at decentralized compared with centralized LCS programs. Our results highlight the need for further study of healthcare system–level mechanisms to optimize longitudinal LCS care.